论文部分内容阅读
目的探讨吉非替尼(Gefitinib)与染料木黄酮(Genistein)联合应用对人非小细胞肺癌(NSCLC)细胞株H1975增殖与凋亡的影响。方法采用MTT比色法观察两种药物单用及联用对人非小细胞肺癌细胞株H1975细胞增殖的影响;流式细胞仪检测细胞凋亡率;Western blotting检测凋亡相关基因PARP和caspase-3的蛋白水平。结果Gefitinib与Genistein联合用药对H1975细胞的抗增殖效应优于Gefitinib单药组,协同增效作用明显,抑制率升高,并呈现剂量依赖的抗增殖效应,差异有统计学意义(P<0.05);两药联用细胞凋亡率为(68.70±7.13)%,与正常对照组的(3.12±0.75)%、Genistein组的(35.95±2.32)%、Gefitinib组的(42.03±4.38)%比较,差异有统计学意义(P<0.05);与单药组比较,两药联用组PARP和caspase-3的断裂片段水平增加。结论 Genistein可以增强Gefitinib对H1975细胞的增殖抑制作用并促进肿瘤细胞的凋亡。
Objective To investigate the effects of gefitinib combined with genistein on the proliferation and apoptosis of human non-small cell lung cancer (NSCLC) cell line H1975. Methods MTT assay was used to observe the effects of two drugs alone and in combination on the proliferation of human non-small cell lung cancer cell line H1975; the apoptosis rate was detected by flow cytometry; the expressions of PARP and caspase- 3 protein levels. Results The antiproliferative effect of Gefitinib combined with Genistein on H1975 cells was better than that of Gefitinib alone. The combination of Gefitinib and Genistein had a synergistic effect, a high inhibition rate and a dose dependent antiproliferative effect, with significant difference (P <0.05) (68.70 ± 7.13)%, compared with (3.12 ± 0.75)% in normal control group, (35.95 ± 2.32)% in Genistein group and (42.03 ± 4.38)% in Gefitinib group, The differences were statistically significant (P <0.05). Compared with the single drug group, the levels of cleaved fragments of PARP and caspase-3 increased in both groups. Conclusion Genistein can enhance the inhibitory effect of Gefitinib on the proliferation of H1975 cells and promote the apoptosis of tumor cells.